L. S. Wyrwicz - Oncol & Radiotherapy, Mar Sklodowska Curie Natl Res Inst Oncol

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 22 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

395MO Tislelizumab (TIS) + Chemotherapy (CT) Vs Placebo (PBO) + CT in Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC): PD-L1 Biomarker Analysis from RATIONALE-306

E. Raymond, J. Xu, K. Kato, R. Hubner, Y. Shu, S.R. Park, T. Kojima,L.S. Wyrwicz, D. Tougeron, K. Geboes,E. Van Cutsem,R.A. Pazo Cid, A. Zaanan,S-A. McLachlan, H. Wu, J. Shi, L. Li, S. Yan, H. Yoon

Annals of Oncology (2024)

Cited0Views0Bibtex

LBA3 Final Analysis of the Phase III KEYNOTE-585 Study of Pembrolizumab Plus Chemotherapy Vs Chemotherapy As Perioperative Therapy in Locally-Advanced Gastric and Gastroesophageal Junction Cancer

K. Shitara, S.Y. Rha,L.S. Wyrwicz, T. Oshima,N. Karaseva, M. Osipov, H. Yasui,H. Yabusaki, S. Afanasyev,Y-K. Park,S-E. Al-Batran, T. Yoshikawa,P.E. Yanez Weber, M. Di Bartolomeo, S. Lonardi, X. Fang,C-S. Shih,P. Bhagia,Y-J. Bang

Annals of Oncology (2024)

Cited0Views0Bibtex

1437P Tislelizumab (TIS) + Chemotherapy (CT) Vs Placebo (PBO) + CT in HER2-negative Advanced or Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma (GC/GEJC): RATIONALE-305 Study Minimum 3-Year Survival Follow-Up

M. Cruz-Correa,D-Y. Oh, K. Kato, J. Tabernero, Y. Bai, J. Shi, K-W. Lee, H. Hirano, D.R. Spigel,L.S. Wyrwicz,R.A. Pazo Cid,A. Cubillo Gracian, L. Li, Y. Xu, T. Sheng, S. Yang, R-H. Xu, M. Moehler

Annals of Oncology (2024)

Cited0Views0Bibtex

398P Nivolumab (NIVO) Plus Chemotherapy (chemo) or Ipilimumab (IPI) Vs Chemo As First-Line (1L) Treatment for Advanced Esophageal Squamous Cell Carcinoma (ESCC): Additional Analysies from 45-Month (mo) Follow-Up of CheckMate 648

A. Adenis, I. Chau, J.A. Ajani, Y. Kitagawa, J. Xu,L.S. Wyrwicz, S. Motoyama, T. Ogata, H. Kawakami, C-H. Hsu,F. El Hajbi, M. Di Bartolomeo,M.I. Braghiroli,E. Holtved,M. Blum Murphy, J. Zhang, N. Hu, Y. Matsumura, K. Kato, Y. Doki

Annals of Oncology (2024)

Cited0Views0Bibtex

1400O Final Overall Survival for the Phase III, KEYNOTE-811 Study of Pembrolizumab Plus Trastuzumab and Chemotherapy for HER2+ Advanced, Unresectable or Metastatic G/GEJ Adenocarcinoma

Y.Y. Janjigian,A. Kawazoe, Y. Bai, J. Xu, S. Lonardi,J-P. Metges,P.E. Yanez Weber,L.S. Wyrwicz, L. Shen, Y.V. Ostapenko, M. Bilici, H.C. Chung, K. Shitara, M. Mahave,E. Van Cutsem, J. Tabernero, L. Xu,K. Sharan,P. Bhagia, S.Y. Rha

Annals of Oncology (2024)

Cited0Views0Bibtex

1451P Neoadjuvant and Adjuvant Pembrolizumab (pembro) + Chemotherapy (chemo) for Locally Advanced Gastric or Gastroesophageal Junction (G/GEJ) Cancer: Patient-reported Outcomes (pros) from the Phase III KEYNOTE-585 Study

Annals of Oncology (2024)

Cited0Views0Bibtex

399P A Quality-adjusted Time Without Symptoms and Toxicity (Q-Twist) Analysis Comparing Nivolumab Plus Chemotherapy (N+CT) or Nivolumab Plus Ipilimumab (N+I) Vs CT in Patients (pts) with Tumor Cell PD-L1 ≥ 1% Advanced Esophageal Squamous Cell Carcinoma (ESCC): CheckMate 648

I. Chau,J.A. Bridgewater,L.S. Wyrwicz, M. Greenwood,S.I. Blum,A. Moreno-Koehler, E. Martin, F. Taylor, C. Davis, P. Singh

Annals of Oncology (2024)

Cited0Views0Bibtex

397MO Tislelizumab (TIS) Plus Chemotherapy (CT) Vs Placebo (PBO) Plus CT in HER2-negative Advanced or Metastatic Gastric or Gastro-Esophageal Junction Adenocarcinoma (GC/GEJC): PD-L1 Biomarker Analysis from RATIONALE-305

M. Moehler,D-Y. Oh, K. Kato, J. Tabernero, M. Cruz-Correa,L.S. Wyrwicz,R.A. Pazo Cid,A. Cubillo,L. Evesque, L. Fornaro,E. Dotan, C. Morgan, L. Li, Y. Xu, T. Sheng, S. Yang,H. Hu, R-H. Xu

Annals of Oncology (2024)

Cited0Views0Bibtex

419P Nivolumab (NIVO) + Chemotherapy (chemo) Vs Chemo As First-Line (1L) Treatment for Advanced Gastric Cancer/gastroesophageal Junction Cancer/esophageal Adenocarcinoma (GC/GEJC/EAC): Additional Analyses from 4-Year (y) Follow-Up (FU) of CheckMate 649

L.S. Wyrwicz, K. Shitara, M. Moehler, J.A. Ajani, L. Shen, M. Garrido, C.E. Gallardo Araneda, K. Yamaguchi, J. Cleary,E. Elimova,R. Brugés Maya,M.V. Karamouzis,T. Skoczylas, A.C. Bragagnoli, T. Liu,M. Tehfe, K. Feeney, R. Wang, J. Zhang,Y.Y. Janjigian

Annals of Oncology (2024)

Cited0Views0Bibtex

LBA73 Pathological Complete Response (pcr) to Durvalumab Plus 5-Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel (FLOT) in Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC): Interim Results of the Global, Phase III MATTERHORN Study

D-Y. Oh,Y. Y. Janjigian, S-E. Al-Batran,Z. A. Wainberg,E. van Cutsem,D. Molena,K. Muro,W. J. Hyung,L. S. Wyrwicz,T. Omori,M. Moehler,M. Garrido, S. Cunha Sousa Oliveira, M. Liberman, V. Castro Oliden,M. Bilici,J. Kurland,I. Xynos,H. Mann,J. Tabernero

Annals of Oncology（2023）

Cited1Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn